Key result
Serum resistin levels are higher in diabetic acute STEMI patients versus non-diabetics and healthy controls.
Why the study?
Are serum resistin concentrations elevated in patients with acute STEMI and type 2 diabetes mellitus compared to those without diabetes and healthy controls?
Observational (n=55)
Are serum resistin concentrations elevated in patients with acute STEMI and type 2 diabetes mellitus compared to those without diabetes and healthy controls?
p-value: p=<0.05
Serum resistin is elevated in acute STEMI, particularly in patients with concurrent type 2 diabetes, and correlates with troponin I, suggesting potential utility as a diagnostic biomarker.
May support resistin as biomarker in diabetic STEMI; hypothesis-generating and requires prospective validation.
AIM: Human resistin is an adipokine, with a possible link to coronary heart disease, and the relationship between serum resistin, insulin resistance, and type 2 diabetes mellitus (T2DM) remains controversial. Therefore, this study assessed serum resistin in patients with acute ST segment elevation myocardial infarction (STEMI), with and without T2DM. METHODS: Between June 2009 and July 2010, 55 subjects were recruited into three groups: 20 non-diabetic patients with acute STEMI (group 1), 20 diabetic patients with acute STEMI (group 2), and 15 healthy controls (group 3). Concentrations of serum lipids, fasting blood glucose (FBG), insulin, troponin I, creatine kinase (CK), lactate dehydrogenase (LDH), and resistin, were estimated. RESULTS: Concentrations of serum total cholesterol, low density lipoprotein cholesterol, FBG, troponin I, CK, LDH, and resistin were significantly higher in group 2 subjects, than in those in groups 1 and 3 (p<0.05). In group 2, serum resistin was positively correlated with serum troponin I and triglycerides (r=0.59, p<0.05, and r=0.47, p<0.05, respectively), but was negatively correlated with high density lipoprotein cholesterol (r=-0.46, p<0.05). However, in this group, serum resistin was not correlated with age, gender, body mass index (BMI), total cholesterol, FBG, insulin, CK, LDH, and the calculated homeostasis model for insulin resistance (HOMA-IR) (p>0.05). Regarding group 1, serum resistin was not correlated to any of these studied parameters (p>0.05). CONCLUSIONS: Serum resistin concentrations are elevated in patients with acute STEMI. This increase is more prominent in patients with T2DM than in those without. However, serum resistin is not correlated with age, gender, BMI, and insulin resistance. These data suggest that serum resistin concentration might be used as a diagnostic biomarker for acute STEMI.
No takes yet. Share an insight, caveat, or question.
Korah et al. (2011) conducted an observational in Acute ST segment elevation myocardial infarction (STEMI) (n=55). Acute STEMI with T2DM vs. Acute STEMI without T2DM and healthy controls was evaluated on Serum resistin concentrations (p=<0.05). Serum resistin concentrations were significantly higher in diabetic patients with acute STEMI compared to non-diabetic STEMI patients and healthy controls (p<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: